Successful Treatment of EGFR-Mutant Synchronous SCLC and Lung Adenocarcinoma With Osimertinib

被引：3
|
作者：
Batra, Ullas [1 ,4 ]
Nathany, Shrinidhi [2 ]
Sharma, Mansi [1 ]
Mehta, Anurag [2 ]
Jain, Parveen [1 ]
Bansal, Abhishek [3 ]
机构：
[1] Rajiv Gandhi Canc Inst & Res Ctr, Dept Med Oncol, New Delhi, India
[2] Rajiv Gandhi Canc Inst & Res Ctr, Mol Diagnost, New Delhi, India
[3] Rajiv Gandhi Canc Inst & Res Ctr, Dept Radiol, New Delhi, India
[4] Rajiv Gandhi Canc Inst & Res Ctr, Dept Med Oncol, Sect 5, New Delhi 110085, India
来源：
JTO CLINICAL AND RESEARCH REPORTS | 2021年 / 2卷 / 01期
关键词：
TRANSFORMATION; CANCER;
D O I：
10.1016/j.jtocrr.2020.100098
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Capmatinib and Osimertinib Combination Therapy for EGFR-Mutant Lung Adenocarcinoma
    Gautschi, Oliver
    Menon, Roopika
    Bertrand, Miriam
    Murer, Christian
    Diebold, Joachim
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (01) : E13 - E15
  • [2] Ibrutinib Treatment and EGFR-mutant Lung Adenocarcinoma
    Shulman, Katerina
    Kazarin, Olga
    Tannous, Elias
    Sofer, Orit
    [J]. ISRAEL MEDICAL ASSOCIATION JOURNAL, 2021, 23 (06): : 385 - 386
  • [3] Clinical and genetic characteristics of EGFR-mutant lung adenocarcinoma transformed SCLC.
    Gu, Linping
    Zhang, Bei
    Zhang, Ding
    Jian, Hong
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [4] EGFR-mutant lung adenocarcinoma associated with antisynthetase syndrome successfully treated with osimertinib
    Hara, Reina
    Kanazu, Masaki
    Iwai, Ami
    Kuge, Tomoki
    Ishijima, Mikako
    Uenami, Takeshi
    Akazawa, Yuki
    Yano, Yukihiro
    Yamaguchi, Toshihiko
    Mori, Masahide
    [J]. THORACIC CANCER, 2021, 12 (09) : 1441 - 1444
  • [5] Overcoming acquired resistance following osimertinib administration in EGFR-mutant lung adenocarcinoma
    Kaira, Kyoichi
    Imai, Hisao
    Kagamu, Hiroshi
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (05) : 1177 - 1182
  • [6] Rhabdomyosarcomatous Transformation as a Mechanism of Resistance to Osimertinib and Savolitinib in EGFR-Mutant Lung Adenocarcinoma With METamp After Osimertinib First-Line Treatment
    Corassa, Marcelo
    Abreu, Rodrigo Fonseca
    Cordeiro de Lima, Vladmir Claudio
    Torrezan, Giovana Tardim
    Cavalher, Felicia Peterson
    Silva, Tullio Novaes
    de Oliveira, Thiago Bueno
    Freitas, Helano Carioca
    Carraro, Dirce Maria
    Costa, Felipe D'Almeida
    [J]. JCO PRECISION ONCOLOGY, 2022, 6
  • [7] Cardiac Risk-Informed Treatment of EGFR-Mutant Lung Cancer With Osimertinib
    Piper-Vallillo, Andrew J.
    Sequist, Lecia V.
    [J]. JACC: CARDIOONCOLOGY, 2019, 1 (02): : 179 - 181
  • [8] Emerging Treatment Paradigms for EGFR-Mutant Lung Cancers Progressing on Osimertinib: A Review
    Piper-Vallillo, Andrew J.
    Sequist, Lecia, V
    Piotrowska, Zofia
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (25) : 2926 - +
  • [9] Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib
    Oztan, A.
    Fischer, S.
    Schrock, A. B.
    Erlich, R. L.
    Lovly, C. M.
    Stephens, P. J.
    Ross, J. S.
    Miller, V.
    Ali, S. M.
    Ou, S. -H. I.
    Raez, L. E.
    [J]. LUNG CANCER, 2017, 111 : 84 - 87
  • [10] Afatinib monotherapy in EGFR-mutant lung adenocarcinoma
    Gilbert, Judith A.
    [J]. LANCET ONCOLOGY, 2013, 14 (09): : E345 - E345
12345